Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

Phase 3

Completed

Conditions: Cold Urticaria

Interventions: Drug: Dupilumab SAR231893
Drug: Placebo
Drug: Non sedating H1-antihistamine

First Posted Date: 2020-12-23

Last Posted Date: 2024-02-21

Lead Sponsor: Sanofi

Target Recruit Count: 82

Registration Number: NCT04681729

Locations: 🇯🇵
Investigational Site Number :3920008, Kamimashiki Gun, Kumamoto, Japan
🇺🇸
Allergy and Asthma Medical Group and Research Center-Site Number:8400001, San Diego, California, United States
🇺🇸
Johns Hopkins University (Asthma and Allergy Center)-Site Number:8400005, Baltimore, Maryland, United States

and more 30 locations

Dupilumab in CRSsNP

Phase 3

Completed

Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Sinus Disorder
Respiratory Disorder
Chronic Sinusitis
Sinusitis

Interventions: Drug: Dupilumab SAR231893
Drug: Placebo

First Posted Date: 2020-12-22

Last Posted Date: 2025-02-10

Lead Sponsor: Sanofi

Target Recruit Count: 71

Registration Number: NCT04678856

Locations: 🇺🇦
Investigational Site Number : 8040008, Kyiv, Ukraine
🇺🇸
Pharmaceutical Research & Consulting, Inc. Site Number : 8400006, Dallas, Texas, United States
🇺🇸
Alamo ENT Associates Site Number : 8400021, San Antonio, Texas, United States

and more 55 locations

Dupilumab in Japanese Patients With Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab SAR231893
Drug: Placebo

First Posted Date: 2020-12-22

Last Posted Date: 2024-05-16

Lead Sponsor: Sanofi

Target Recruit Count: 62

Registration Number: NCT04678882

Locations: 🇯🇵
Investigational Site Number : 3920011, Nagoya-shi, Aichi, Japan
🇯🇵
Investigational Site Number : 3920014, Toyoake-shi, Aichi, Japan
🇯🇵
Investigational Site Number : 3920015, Fukutsu-shi, Fukuoka, Japan

and more 16 locations

A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Rosuvastatin
Drug: SPC ezetimibe/rosuvastatin
Drug: Rosuvastatin active capsule
Drug: Placebo

First Posted Date: 2020-12-16

Last Posted Date: 2022-06-23

Lead Sponsor: Sanofi

Target Recruit Count: 305

Registration Number: NCT04669041

Locations: 🇨🇳
Investigational Site Number :1560006, Hohhot, China
🇨🇳
Investigational Site Number :1560045, Changchun, China
🇨🇳
Investigational Site Number :1560067, Changchun, China

and more 37 locations

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase 2

Terminated

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)

Interventions: Drug: Isatuximab SAR650984

First Posted Date: 2020-12-09

Last Posted Date: 2024-12-05

Lead Sponsor: Sanofi

Target Recruit Count: 8

Registration Number: NCT04661033

Locations: 🇮🇹
Investigational Site Number : 3800001, Milano, Italy
🇫🇷
Investigational Site Number : 2500001, Creteil Cedex, France
🇬🇧
Investigational Site Number : 8260001, London, London, City Of, United Kingdom

and more 3 locations

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

Phase 2

Completed

Conditions: Pancreatic Carcinoma Metastatic
Breast Cancer Metastatic

Interventions: Drug: tusamitamab ravtansine
Drug: Gemcitabine

First Posted Date: 2020-12-09

Last Posted Date: 2025-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 50

Registration Number: NCT04659603

Locations: 🇹🇷
Investigational Site Number : 7920004, Ankara, Turkey
🇳🇱
Investigational Site Number : 5280001, Rotterdam, Netherlands
🇹🇷
Investigational Site Number : 7920003, Adana, Turkey

and more 26 locations

Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ

Phase 4

Completed

Conditions: Gaucher's Disease

Interventions: Drug: Cerezyme® / Imiglucerase

First Posted Date: 2020-12-07

Last Posted Date: 2024-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 12

Registration Number: NCT04656600

Locations: 🇨🇳
Investigational Site Number : 102, Guangzhou, China
🇨🇳
Investigational Site Number : 107, Beijing, China
🇨🇳
Investigational Site Number : 101, Beijing, China

and more 2 locations

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Phase 1

Recruiting

Conditions: Plasma Cell Myeloma Refractory

Interventions: Drug: Isatuximab
Drug: Dexamethasone
Drug: Pegenzileukin
Drug: Pomalidomide
Drug: SAR439459
Drug: Belantamab mafodotin
Drug: Belumosudil
Drug: Evorpacept

First Posted Date: 2020-11-24

Last Posted Date: 2025-05-22

Lead Sponsor: Sanofi

Target Recruit Count: 197

Registration Number: NCT04643002

Locations: 🇬🇷
Investigational Site Number : 3000001, Athens, Greece
🇺🇸
University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan, United States
🇺🇸
Roswell Park Cancer Institute- Site Number : 8400008, Buffalo, New York, United States

and more 22 locations

Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

Phase 2

Completed

Conditions: Pneumococcal Immunization

Interventions: Biological: Pneumococcal Vaccine Polyvalent-Pneumovax 23
Biological: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
Biological: Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
Biological: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI
Biological: Pneumococcal 13 - valent conjugate vaccine-Prevnar 13

First Posted Date: 2020-10-12

Last Posted Date: 2024-08-27

Lead Sponsor: Sanofi

Target Recruit Count: 750

Registration Number: NCT04583618

Locations: 🇺🇸
Coastal Carolina Research Center - N Charleston Site Number : 8400004, North Charleston, South Carolina, United States
🇺🇸
Velocity Clinical Research, Medford Site Number : 8400010, Medford, Oregon, United States
🇺🇸
Preferred Primary Care Physicians Site Number : 8400009, Pittsburgh, Pennsylvania, United States

and more 14 locations

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

Phase 2

Completed

Conditions: Sjögren's Syndrome
Sjogren's Syndrome

Interventions: Drug: Placebo
Drug: SAR441344

First Posted Date: 2020-10-01

Last Posted Date: 2024-11-11

Lead Sponsor: Sanofi

Target Recruit Count: 84

Registration Number: NCT04572841

Locations: 🇨🇱
Investigational Site Number : 1520001, Santiago, Reg Metropolitana De Santiago, Chile
🇨🇱
Investigational Site Number : 1520004, Viña del Mar, Valparaíso, Chile
🇲🇽
Investigational Site Number : 4840002, Mexicali, Baja California, Mexico

and more 33 locations

Home Terms & Conditions Privacy Policy